Korro Bio Grants Equity Incentives to Two New Hires Under Nasdaq Inducement Rule
Korro Bio, Inc. (KRRO) issued equity incentive awards to two newly hired employees. The company granted non-statutory stock options to purchase a total of 4,000 shares of common stock at an exercise price of $8.88 per share, matching the closing price on October 14, 2026. The grants were made under the company's 2026 Inducement Plan and in compliance with Nasdaq Listing Rule 5635(c)(4).
Inducement awards allow public companies to offer stock option packages to recruit new personnel without requiring explicit shareholder approval for every individual grant. The options carry a ten-year term and vest over four years, with 25% vesting after the first year and the remaining 75% vesting in monthly increments over the following 36 months, provided the employees remain in continuous service.
As a clinical-stage biopharmaceutical business, Korro Bio relies on specialized talent to advance its proprietary OPERA RNA-editing platform. Investors will be watching how these new appointments support the progression of its clinical programs and whether future operational updates help stabilize the stock, which closed down 8.29% at $8.538.
Key points
- Korro Bio granted stock options to purchase 4,000 shares of common stock to two new employees.
- The options feature an exercise price of $8.88 per share, based on the closing market price on October 14, 2026.
- Each grant has a ten-year term and vests over four years, subject to continued employment.
- The awards were issued under Korro's 2026 Inducement Plan in line with Nasdaq Listing Rule 5635(c)(4).
Written by our AI from expert market sources across the web. It can contain mistakes: check the facts before acting on them. Write-ups powered by the free AI API at FreeTheAI.org
How we writeDisclaimerQuestions and answers
Why did Korro Bio issue stock options to new employees?
Korro Bio granted the stock options as an inducement material to recruit two new employees, following Nasdaq Listing Rule 5635(c)(4) guidelines.
What are the terms of Korro Bio's new stock option grants?
The options cover 4,000 shares total at an exercise price of $8.88 per share. They feature a 10-year term and vest over four years, with 25% vesting after one year and the rest vesting monthly over the next three years.
How did Korro Bio stock perform following the announcement?
Korro Bio stock traded at $8.538 per share, down 8.29% for the session.